Empower Tirzepatide: Reading the Evidence Before You Decide

How the SURMOUNT programme built the evidence base

The confidence behind tirzepatide's UK licence comes primarily from a large-scale clinical programme. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight and at least one weight-related condition. After 72 weeks, participants taking the 15mg dose lost an average of around 20–21% of body weight compared with placebo. That is not a rounding artefact or a best-case reading, it is the mean across the trial population, which included people who experienced side effects, people who never reached the top dose, and people who simply had a harder time.

A separate head-to-head study, SURMOUNT-5, placed tirzepatide directly against semaglutide 2.4mg in adults without diabetes over 72 weeks. Tirzepatide produced greater average weight loss. That trial matters because it answers the question patients most often ask: if you are weighing up whether to choose Mounjaro or tirzepatide by its generic name, is there actually a difference between these two medicines, or is the evidence just from separate placebo-controlled studies? There is a difference, and it is measurable. Even so, which medicine suits a particular person depends on their full medical picture, not on a league table of trial averages.

NICE drew on this evidence when it recommended tirzepatide in technology appraisal TA1026 (published December 2024, updated September 2025) for NHS use in adults with a BMI of 35 or above alongside at least one weight-related comorbidity. Lower thresholds apply for some ethnic backgrounds under UK guidance. Private prescribing follows the licensed eligibility criteria in the medicine's SmPC, which set the bar at a BMI of 30 or above, or 27 or above with a qualifying condition.

The mechanism behind the numbers

One misconception worth setting down gently: tirzepatide is sometimes described as simply a stronger version of existing GLP-1 medicines. That framing is understandable but not quite right. It works through two receptors rather than one. GLP-1 (glucagon-like peptide-1) activity slows gastric emptying and increases the feeling of fullness; GIP (glucose-dependent insulinotropic polypeptide) activity adds a complementary signal that influences appetite, fat metabolism and energy use. The two pathways together appear to produce greater weight reduction than either alone, which is what the SURMOUNT-5 head-to-head result reflects in practice.

Treatment begins at the 2.5mg dose. That starting strength exists to let the body settle before any meaningful therapeutic effect builds, which is part of why the early weeks can feel uneventful. Gradual titration, managed by a prescriber, reduces the intensity of the gastrointestinal side effects (nausea, loose stools, indigestion) that are most common in the first weeks after starting or after each dose step. The NHS tirzepatide page describes what to expect and when to seek help.

For a fuller picture of how Mounjaro sits within the broader landscape of weight-loss treatments, the treatment overview on this site walks through the options currently available in the UK.

What the evidence does not tell you

Trial averages describe populations, not individuals. Some participants in SURMOUNT-1 lost considerably more than 20%; others lost less, or discontinued. Age, starting weight, dietary habits, sleep, other medicines and underlying health conditions all influence how treatment unfolds for any one person. That is not a reason for pessimism, it is a reason to have a proper clinical conversation rather than selecting a dose or a timeline based on headline figures.

There is also a supply-chain question that the evidence base naturally cannot address: genuine, pharmacy-dispensed tirzepatide from the licensed UK supply chain is not the same product as the counterfeit pens the MHRA has warned about publicly, fake versions have been found to contain insulin. If you are thinking about private treatment, verifying that a pharmacy appears on the GPhC register is the simplest practical check. Any seller offering these medicines without a prescription should be treated as a serious red flag.

Cost is another dimension the trials do not touch. If you want to understand how private tirzepatide pricing is structured in the UK (what a legitimate quoted price should include and what it often omits) the tirzepatide information page covers that context, and the Mounjaro access guide explains the steps involved in getting a private prescription through a regulated pharmacy.

The prescriber's role in translating evidence into a treatment plan

Clinical trial results become useful to an individual only when a prescriber reviews that person's health history, current medicines, weight trajectory and goals. At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber on the same day it is submitted, a person, not software. Identity is verified, weight is confirmed on video, and the prescriber considers whether tirzepatide is appropriate, which starting point makes sense, and what to watch for. For those curious about where treatment can lead, our guide to reaching the tirzepatide 30mg maintenance stage explains what higher doses involve and how titration typically progresses.

If approved, treatment is dispatched the same day for orders placed before midday, Monday to Friday, and delivered free the next working day by DPD in plain, unbranded packaging. Those starting out can find detailed guidance on our tirzepatide 10mg dose page, which covers what to expect as you move through the early titration steps. For questions before or after starting, the FAQs cover the most common practical points, and aftercare support is available seven days a week.

If you are ready to talk through whether tirzepatide is the right option for you, speak to our prescribers through a free consultation, there is no obligation, and the assessment is there to give you an honest clinical answer, whatever that turns out to be.